ALP AI
ALP AI offers a platform that helps drug developers reduce risk by predicting immune responses to biologics early. It uses human tonsil organoids combined with generative AI to forecast anti-drug antibodies before trials. The core technology combines tissue-based assays with AI models to identify immunogenicity risks. The product targets B2B biotech and pharma customers seeking safer antibody therapies. With this approach, ALP AI aims to scale biopharma programs and accelerate development timelines.
ALP AI
ALP AI offers a platform that helps drug developers reduce risk by predicting immune responses to biologics early. It uses human tonsil organoids combined with generative AI to forecast anti-drug antibodies before trials. The core technology combines tissue-based assays with AI models to identify immunogenicity risks. The product targets B2B biotech and pharma customers seeking safer antibody therapies. With this approach, ALP AI aims to scale biopharma programs and accelerate development timelines.